Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy

Outcomes remain poor for patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (R/R B‐NHL). While chimeric antigen receptor (CAR) T‐cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 × CD3 bispecific antibody tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinstock, Matt, Elavalakanar, Pavania, Bright, Susan, Ambati, Srikanth R., Brouwer‐Visser, Jurriaan, Pourpe, Stephane, Fiaschi, Nathalie, Jankovic, Vladimir, Thurston, Gavin, Deering, Raquel P., Chaudhry, Aafia, Joyce, Robin, Arnason, Jon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy–Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796753/
https://www.ncbi.nlm.nih.gov/pubmed/35892294
http://dx.doi.org/10.1111/bjh.18383
Descripción
Sumario:Outcomes remain poor for patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (R/R B‐NHL). While chimeric antigen receptor (CAR) T‐cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 × CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B‐NHL in a first‐in‐human trial (NCT02290951). Here, we document two patients with diffuse large B‐cell lymphoma refractory to CART‐cell therapy. Both achieved complete responses that remain ongoing for ≥2 years following odronextamab. Neither patient experienced Grade ≥3 cytokine release syndrome or Grade ≥3 neurological adverse events during treatment.

Ejemplares similares